Will GLP-1-based therapies reshape the epidemiology of MASLD? An emerging public health perspective

Evelyn Nunes Goulart da Silva Pereira, Karine Lino Rodrigues

Open source

DOI
10.3389/fendo.2026.1981916
Published
2026-10-23
Container
Frontiers in Endocrinology
Publisher
Frontiers Media SA
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3389/fendo.2026.1981916,
  title = {Will GLP-1-based therapies reshape the epidemiology of MASLD? An emerging public health perspective},
  author = {Evelyn Nunes Goulart da Silva Pereira and Karine Lino Rodrigues},
  year = {2026},
  journal = {Frontiers in Endocrinology},
  doi = {10.3389/fendo.2026.1981916},
  url = {https://doi.org/10.3389/fendo.2026.1981916}
}

RIS

TY  - JOUR
TI  - Will GLP-1-based therapies reshape the epidemiology of MASLD? An emerging public health perspective
AU  - Evelyn Nunes Goulart da Silva Pereira
AU  - Karine Lino Rodrigues
PY  - 2026
JO  - Frontiers in Endocrinology
DO  - 10.3389/fendo.2026.1981916
UR  - https://doi.org/10.3389/fendo.2026.1981916
ER  - 

APA

Pereira, E. N. G. D. S., & Rodrigues, K. L. (2026). Will GLP-1-based therapies reshape the epidemiology of MASLD? An emerging public health perspective. Frontiers in Endocrinology. https://doi.org/10.3389/fendo.2026.1981916

Source records